Con: Are we ready to translate Alzheimer's disease-modifying therapies to people with down syndrome?

Alzheimer's Research and Therapy

Volumn 6, Issue 5-8, 2014, Pages

  Head, Elizabeth ^a   Schmitt, Frederick A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ANXIETY; CEREBROSPINAL FLUID; CHROMOSOME 21; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DOWN SYNDROME; HUMAN; IMMUNOTHERAPY; INTELLECTUAL IMPAIRMENT; MILD COGNITIVE IMPAIRMENT; MORBIDITY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT OUTCOME;

EID: 84907063733     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-014-0061-6     Document Type: Review

References (16)

1. Alzheimer's disease in Down syndrome. E Head, D Powell, BT Gold, FA Schmitt, Eur J Neurodegener Dis 2012 1 353 363
2. Genetic and host factors for dementia in Down's syndrome. N Schupf, GH Sergievsky, Br J Psychiatry 2002 180 405 410 10.1192/bjp.180.5.405 11983636
3. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. K Wisniewski, H Wisniewski, G Wen, Ann Neurol 1985 17 278 282 10.1002/ana.410170310 3158266
4. Atypical aging in Down syndrome. WB Zigman, Dev Disabil Res Rev 2013 18 51 67 10.1002/ddrr.1128 23949829
5. Diagnosing Alzheimer's dementia in Down syndrome: problems and possible solutions. RE Nieuwenhuis-Mark, Res Dev Disabil 2009 30 827 838 10.1016/j.ridd.2009.01.010 19269132
6. Prevalence of dementia in intellectual disability using different diagnostic criteria. A Strydom, G Livingston, M King, A Hassiotis, Br J Psychiatry 2007 191 150 157 10.1192/bjp.bp.106.028845 17666500
7. Dementia and mild cognitive impairment in adults with intellectual disability: issues of diagnosis. SJ Krinsky-McHale, W Silverman, Dev Disabil Res Rev 2013 18 31 42 10.1002/ddrr.1126 23949827
8. Current Alzheimer's disease clinical trials: methods and placebo outcomes. LS Schneider, M Sano, Alzheimers Dement 2009 5 388 397 10.1016/j.jalz.2009.07.038 19751918
9. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. SJ Teipel, H Hampel, Behav Genet 2006 36 405 415 10.1007/s10519-006-9047-x 16485178
10. Using positron emission tomography and carbon 11-labeled Pittsburgh compound B to image brain fibrillar beta-amyloid in adults with Down syndrome: safety, acceptability, and feasibility. J Landt, JC D'Abrera, AJ Holland, FI Aigbirhio, TD Fryer, R Canales, YT Hong, DK Menon, JC Baron, SH Zaman, Arch Neurol 2011 68 890 896 10.1001/archneurol.2011.36 21403005
11. https://dsconnect.nih.gov/ DS-Connect™: The Down Syndrome Registry.
12. Down syndrome and dementia: seizures and cognitive decline. IT Lott, E Doran, VQ Nguyen, A Tournay, N Movsesyan, DL Gillen, J Alzheimers Dis 2012 29 177 185 22214782
13. Frontal white matter integrity in adults with Down syndrome with and without dementia. D Powell, A Caban-Holt, G Jicha, W Robertson, R Davis, BT Gold, FA Schmitt, E Head, Neurobiol Aging 2014 35 1562 1569 10.1016/j.neurobiolaging.2014.01.137 24582640
14. Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis. DM Wilcock, WS Griffin, J Neuroinflammation 2013 10 84 10.1186/1742-2094-10-84 23866266
15. Targeting the beta secretase BACE1 for Alzheimer's disease therapy. R Yan, R Vassar, Lancet Neurol 2014 13 319 329 10.1016/S1474-4422(13)70276-X 24556009
16. Down's syndrome and Alzheimer's disease: towards secondary prevention. S Ness, M Rafii, P Aisen, M Krams, W Silverman, H Manji, Nat Rev Drug Discov 2012 11 655 656 10.1038/nrd3822 22935789